Targeted Therapy Shrinks Lung Cancer Brain Tumors
In a small early study, most patients with lung cancer that spread to the brain saw tumors shrink after targeted radiation.
Updated on Nov. 4, 2026 in Cancer
A Chinese study of 14 advanced lung cancer patients with brain metastases found that Lu-177 FAP-2286, a targeted radiopharmaceutical therapy, shrank tumors in more than half of the participants. The results were published in Scientific Reports on November 3, 2026, and the researchers say larger randomized trials are needed before it could be considered a standard option.
Why it matters
Brain metastases from lung cancer are difficult to treat, and current brain-directed options are limited for many patients. This small early study suggests a new targeting approach worth testing more rigorously, which is why the researchers are calling for multicenter randomized trials.
This was a single-center study of 14 advanced lung cancer patients with brain metastases who had already failed at least one prior line of treatment. Results were 57.1% intracranial objective response and 92.9% disease control by RECIST 1.1, with median overall survival of 11.0 months, but the study had no randomized comparison group, so these figures cannot be compared directly against standard therapies.
The players
Scientific Reports
An open-access peer-reviewed journal from Nature Portfolio that publishes research across the natural and health sciences.
The details
Lu-177 FAP-2286 is a radiopharmaceutical that delivers radiation directly to cells that carry fibroblast activation protein, a molecule found on cancer-associated fibroblasts in brain metastatic lesions and largely absent from normal brain tissue. Patients received 7.4 GBq per cycle for a minimum of two cycles, with a mean of 3.1 cycles overall. Responses were assessed four weeks after the second cycle using RECIST 1.1 and PERCIST 1.0, with all brain lesions tracked as target lesions. Patients who responded metabolically had longer survival, with median progression-free survival of 9.0 months versus 6.0 months and median overall survival of 13.0 versus 9.0 months.
Timeline
November 3, 2026: Study published in Scientific Reports
Health Landscape
Most brain-directed treatments for lung cancer metastases, including whole-brain radiotherapy and stereotactic radiosurgery, are local and do not reach widespread disease. This early FAP-2286 study places a systemically delivered, target-specific radiopharmaceutical into a space where options for patients who have already progressed on other therapies remain limited.
For someone living with lung cancer that has spread to the brain, this early research is a reason to ask an oncologist which brain-directed and systemic options are currently available. Because this study is small and preliminary, it should not be read as a treatment that is available now; worth discussing with your doctor whether any clinical trial enrolling patients with brain metastases might be appropriate.
The takeaway
Targeted radiopharmaceuticals are an emerging area of cancer research, and this early study points to a possible new option for brain metastases from lung cancer. Anyone with brain spread who wants to know about trials should raise the question with their oncology team.
Further reading
For broader context on treatment approaches, see the Cancer section.
Source note: This article includes information reported by AuntMinnie.
